8月25日 - ** Coya Therapeutics COYA.O股价盘前上涨7.9%至7.40美元
** 美国食品和药物管理局（FDA）批准该制药公司研究其药物COYA 302，作为肌萎缩性脊髓侧索硬化症的潜在治疗药物(ALS) 在一项中期研究中
** FDA接受新药研究申请后，印度制药商雷迪博士实验室REDY.NS将向Coya公司支付420万美元的里程碑款项。
** ALS 又称卢伽雷氏病，是一种罕见的神经系统疾病，会影响大脑和脊髓中的运动神经元，导致肌肉无力、瘫痪，最终死亡。
** 截至上日收盘，股价累计上涨 19.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.